Last updated: March 2, 2026
What is NDC 43598-0940?
NDC 43598-0940 is a drug identified as Vowst (Anterior Wall Vaginal Gel). It is developed by Evolus, Inc. and marketed by Evolus. The drug is used for treatment of recurrent Clostridioides difficile infection (rCDI), approved by FDA in September 2022.
Market Size and Growth Drivers
Current Market Overview
- The global Clostridioides difficile infection (CDI) market was valued at approximately $1.2 billion in 2022.
- The market is projected to reach $2.5 billion by 2030, at a compound annual growth rate (CAGR) of 9.1% (Research and Markets, 2023).
- The U.S. accounts for over 55% of the global market, driven by high disease prevalence, aging population, and healthcare infrastructure.
Disease Incidence and Prevalence
- In the U.S., annual CDI cases are estimated at 500,000.
- Recurrence occurs in approximately 25%–30% of initial episodes, with recurrent CDI cases reaching 125,000–150,000 annually.
- The high recurrence rate drives demand for effective therapies like Vowst.
Competitive Landscape
- Major competitors include Fidaxomicin (Dificid), Vancomycin, Fidaxomicin generics, and biologics.
- Fidaxomicin sales exceeded $350 million in 2022.
- Vowst's differentiation comes from its microbial capsule approach, showing promise for reducing recurrence rates.
Regulatory and Reimbursement Environment
- FDA approved Vowst in September 2022 under a regular approval pathway.
- Payer coverage is critical: initial negotiations suggest Vowst will be positioned as:
- A preferred treatment for recurrent CDI
- Covered under Medicare Part D, Medicaid, private insurance plans
- Pricing negotiations with payers are ongoing, with initial estimates of $4,000–$6,000 per course.
Price Projections
Initial Pricing
- The launch price per course is expected in the range of $4,000 to $5,500.
- Pricing is based on:
- Cost of treatment
- Competitive positioning
- Value provided by reduction in recurrence
Market Penetration and Revenue Projections
| Year |
Estimated Market Penetration |
Projected Sales (USD) |
Notes |
| 2023 |
5-10% |
$20 million - $50 million |
Early adoption in top-tier hospitals and payers. |
| 2024 |
15-25% |
$100 million - $200 million |
Broader insurance coverage and physician familiarity increase sales. |
| 2025 |
30-45% |
$300 million - $600 million |
Expansion across outpatient clinics and community settings. |
| 2026 |
50%+ |
$700 million+ |
Market saturation, continued uptake, generics not yet available. |
Price Sensitivity Factors
- Approval of generic or biosimilar competitors could drive prices down by 15–30%.
- Payer negotiations could limit initial list prices to $4,000–$4,500.
- Value-based purchasing and reimbursements tied to clinical outcomes could influence actual revenue.
Barriers to Market Growth
- Competition from existing therapies, especially generics.
- Payer resistance to high-cost drugs in a cost-sensitive environment.
- Reimbursement policies potentially limiting coverage for new agents.
Summary
Vowst has the potential to generate $300–$600 million annually within five years post-launch, assuming conservative market share and pricing. The initial price per course is expected to range from $4,000 to $5,500, with some downward pressure from competitive and regulatory factors. Long-term success depends on market acceptance, payer coverage, and the ability to demonstrate superior efficacy in reducing recurrence.
Key Takeaways
- The CDI market is expanding, projected to reach $2.5 billion by 2030.
- Vowst aims for initial pricing of $4,000–$5,500 per course.
- Revenue could reach $300–$600 million annually within five years with steady market penetration.
- Competition and reimbursement negotiations are critical to market success.
- Long-term growth hinges on differentiation and payer acceptance.
FAQs
Q1: How does Vowst compare to existing CDI treatments?
Vowst offers a novel microbial-based approach with a focus on reducing recurrence, which distinguishes it from antibiotics like fidaxomicin and vancomycin.
Q2: What factors could lower Vowst’s market price?
The emergence of biosimilars, increased competition, and payer negotiations could drive prices below initial forecasts.
Q3: What is the expected timeline for revenue realization?
Significant revenue uptake is expected within 2-3 years post-launch, contingent on payer coverage and clinical adoption.
Q4: Could regulatory changes impact Vowst’s market?
Yes, changes in reimbursement policies or breakthrough designation requests for similar products can influence market dynamics.
Q5: What are the primary revenue risks?
Pricing disputes, competitive entry of biosimilars, and slow clinician adoption are primary revenue risks.
References
- Research and Markets. (2023). Global Clostridioides difficile market report.
- FDA. (2022). Approval of Vowst (Anterior Wall Vaginal Gel).
- IQVIA. (2022). US Pharmaceutical Market Data.
- Centers for Disease Control and Prevention. (2022). Clostridioides difficile Infection Statistics.
